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shown in previous studies 5, 6 . Thus, temporary gut microbiota eradication protected those mice from developing mechanical hyperalgesia. The same phenomenon was observed in male and female mice, in rats and in a spontaneous pain-behavior test (Supplementary Fig. 2a-c) . Moreover, we ruled out the possibility that mere exposure to antibiotics directly influences oxaliplatin-induced mechanical hyperalgesia, as intrathecal injection of these antibiotics did not change oxaliplatininduced mechanical hyperalgesia (Supplementary Fig. 2d ).
Next, we compared mechanical hyperalgesia in oxaliplatin-treated germ-free (GF) mice and specific pathogen-free (SPF) mice. Mechanical hyperalgesia only developed in SPF mice, but not in GF mice (Fig. 1e) , indicating that, similarly to the effect of gut microbiota eradication in abx mice, the GF status also prevented oxaliplatin-induced mechanical hyperalgesia. Note that one limitation of the GF mice study was that the behavioral testing period lasted for 3 weeks, and we cannot completely rule out potential contamination of GF mice during the testing period. To confirm that gut microbiota in SPF mice could mediate oxaliplatin-induced mechanical hyperalgesia, we conventionalized GF mice to SPF status by gastric feeding of feces from SPF mice donors. Conventionalization of GF mice to SPF status abrogated the protection mediated by GF status (Fig. 1f) , supporting the hypothesis that the gut microbiota in SPF mice likely mediated oxaliplatin-induced mechanical hyperalgesia.
To investigate the underlying mechanism of the above phenotypes, we first examined the possibility that gut microbiota eradication may alter tissue distribution of oxaliplatin. There were no significant differences in platinum concentrations in the spinal cord, dorsal root ganglion (DRG) and serum between abx mice and H 2 O mice ( Fig. 1g and  Supplementary Fig. 3) . Therefore, gut microbiota eradication did not alter the tissue distribution of oxaliplatin. However, we note that in both groups of mice, the platinum concentrations in DRG were higher than those in the spinal cord or serum ( Fig. 1g ), suggesting that DRG could be a critical site for the pathogenesis of CIPN 7 .
In DRG, levels of IL-6 and TNF-α and their gene transcripts were lower in abx mice than in H 2 O mice after oxaliplatin therapy ( Fig. 1h and Supplementary Fig. 4 ). These differences were only observed in DRG and not in the spinal cord. However, major immune cell proportions including T cells, B cells, monocytes, dendritic cells, NK cells and neutrophils in peripheral blood did not differ between abx mice and H 2 O mice (Supplementary Fig. 5 ). These results support the notion that DRG is a key anatomical site for the pathogenesis of CIPN 7 . Two additional sets of data suggest that gut microbiota eradication led to dampened inflammatory responses in the DRG following exposure to oxaliplatin. First, consistent with the involvement of reactive oxygen species (ROS) in CIPN 8 , we observed that ROS levels in DRG were lower in abx mice than in H 2 O mice, using L-012
Gut microbiota is critical for the induction of chemotherapyinduced pain 1 2 1 4 VOLUME 20 | NUMBER 9 | SEPTEMBER 2017 nature neuroscience B r i e f c o m m u n i c at i o n s chemiluminescence as an indicator for ROS 9 (Fig. 1i) . Second, macrophage infiltration in DRG has recently been identified as a critical event in CIPN 10 . In our experiment, DRG CD11b + and CD45 hi cells, which are presumably macrophages, were less abundant in abx mice than in H 2 O mice ( Fig. 2a,b ) after oxaliplatin therapy.
We stimulated mouse primary macrophages with oxaliplatin in the presence or absence of lipopolysaccharides (LPS), a gram negative bacterial wall component. Without LPS, oxaliplatin at 1 µM failed to stimulate macrophages to secrete IL-6 and TNF-α, and even at a higher oxaliplatin concentration (10 µM), we detected only low concentrations of IL-6 and TNF-α (Fig. 2c) . In the presence of LPS, however, oxaliplatin at 1 or 10 µM robustly and dose-dependently stimulated the production of IL-6 and TNF-α ( Fig. 2c) . Moreover, we confirmed that the LPS and oxaliplatin concentrations we used in cell culture did not increase cell death (Supplementary Fig. 6 ). Therefore, oxaliplatin was ineffective in stimulating inflammatory cytokine production in vitro without the presence of LPS, indicating that a permissive signal would be required for macrophages to mount an inflammatory response against oxaliplatin.
We posit that this permissive signal is likely to be LPS derived from gut microbiota. To examine this hypothesis, we first measured serum and DRG LPS levels in abx mice and H 2 O mice with oxaliplatin or saline treatment. Oxaliplatin treatment increased the serum and DRG LPS levels in both groups of mice compared to saline treatment. However, the serum and DRG LPS levels were significantly higher in H 2 O mice than in abx mice following oxaliplatin treatment ( Fig. 2d) . Next, we examined whether exogenous LPS administration could abrogate the protection of oxaliplatin-induced mechanical hyperalgesia by gut microbiota eradication. Exogenous LPS administration by gastric gavage to abx mice indeed abrogated the protection offered by gut microbiota eradication ( Fig. 3a) . Since LPS is a ligand of Toll-like receptor 4 (Tlr4) 11 , we compared the development of mechanical hyperalgesia following oxaliplatin treatment in Tlr4 knockout (Tlr4 −/− ) mice and littermate heterozygous (Tlr4 +/− ) mice. Oxaliplatin-induced mechanical hyperalgesia was substantially less severe in Tlr4 −/− mice than in their littermate Tlr4 +/− counterparts during the entire observation period (Fig. 3b) , which is in agreement with previous findings on other models of CIPN [12] [13] [14] . Taken together, Temporary eradication of gut microbiota prevents oxaliplatin-induced mechanical hyperalgesia (a-c) Impacts of antibiotic water feeding on mice gut microbiota. Fecal samples were obtained after 3 weeks of antibiotic water (abx mice, n = 10) or regular water (H 2 O mice, n = 10) followed by DNA isolation from these samples. (a) Feeding mice antibiotics reduced bacterial load as determined by semiquantitative real-time PCR. (b) Feeding mice antibiotics reduced the α diversity of microbiota. (c) Feeding mice antibiotics altered bacterial community structure as shown in the phylum analysis. (d) Gut microbiota eradication prevented the development of oxaliplatin-induced mechanical hyperalgesia. Mice were fed on antibiotics water (abx) or regular water (H 2 O) before oxaliplatin or saline treatment (as control). Hindpaw mechanical withdrawal threshold (HWT) was examined at indicated timepoints after oxaliplatin therapy (n = 6 mice in each group; *P < 0.05, H 2 O + oxaliplatin vs. abx + oxaliplatin; **P > 0.05, abx + oxaliplatin vs. abx + saline or H2O + saline). (e) GF status protected mice from oxaliplatin-induced mechanical hyperalgesia. GF or SPF mice were given oxaliplatin or saline. HWT was examined at indicated time points after oxaliplatin therapy (*P < 0.05, SPF + oxaliplatin vs. all other groups; n = 7 mice per group). (f) GF conventionalization abrogated the protection of mechanical hyperalgesia offered by GF status. To conventionalize GF mice, feces from SPF mice were diluted with PBS and administered daily via gastric gavage for 3 weeks. GF and conventionalized GF (GF conv) mice were treated with oxaliplatin or saline. Conventionalization of GF mice abrogated the protection offered by GF status (*P < 0.05, GF conv + oxaliplatin vs. GF + oxaliplatin; n = 8 GF + oxaliplatin, 7 GF + saline, 7 GF conv + oxaliplatin, 6 GF conv + saline). (g) Gut microbiota eradication did not change tissue oxaliplatin distribution (n = 6 mice per group). Spinal cord (SC), serum and DRG concentrations of platinum were determined by inductively coupled plasma mass spectrometry (ICP-MS). Two-way ANOVA suggested abx treatment did not change tissue platinum distribution (P = 0.42) while tissue type had significant influence on platinum levels (P = 0.001). Post hoc t tests (P values in the figure) were performed to identify the impact of tissue type on platinum levels. (h) DRG cytokine levels for IL-6 and TNF-α were lower in mice with eradicated gut microbiota than in mice with normal gut microbiota (n = 6 mice per group); one-way ANOVA indicated a significant difference in DRG samples and subsequent post hoc t tests determined the difference between the abx and H 2 O groups. Sera and spinal cord levels for IL-6 and TNF-α were not significantly different among groups (n = 6 mice per group; one-way ANOVA for sera IL-6 samples, P = 0.58; spinal cord IL-6 samples, P = 0.06; sera TNF-α samples, P = 0.88; spinal cord TNF-α samples, P = 0.75). (i) Reduced ROS in DRG from mice with eradicated gut microbiota. At day 10 after the initiation of oxaliplatin therapy, ROS levels were determined with an IVIS Spectrum in vivo imaging system using L-012 as a chemiluminescent probe (n = 6 mice per group; one-way ANOVA followed by post hoc tests). Error bars in a and d-i indicate mean ± s.e.m.; in b, box plot bottoms and tops indicate 25th and 75th percentiles, respectively, whiskers indicate minima and maxima, and center lines indicate medians.
B r i e f c o m m u n i c at i o n s these results suggest that gut microbiota influenced the development of mechanical hyperalgesia following oxaliplatin therapy through an LPS-TLR4 pathway.
To determine the contribution of TLR4 expressed on hematopoietic versus nonhematopoietic cells to oxaliplatin-induced mechanical hyperalgesia, we carried out a set of experiments using bone marrow chimeric mice. By using reciprocal bone marrow transplantation between wild-type (WT) and Tlr4 −/− mice, we generated bone marrow chimeric mice that only expressed TLR4 on hematopoietic cells and not on nonhematopoietic cells ( Fig. 3c,d) . Successful generation of bone marrow chimera was confirmed by finding that more than 80% and 95% of CD11b + cells in DRG and peripheral blood, respectively, were from the donor origin ( Fig. 3d and Supplementary Fig. 7) . We also found that, when hematopoietic cells were from Tlr4 −/− donors, host mice were protected from oxaliplatin-induced mechanical hyperalgesia regardless of whether their nonhematopoietic cells expressed TLR4 (Fig. 3e) .
These results indicate that the TLR4 expressed on hematopoietic cells was responsible for oxaliplatin-induced mechanical hyperalgesia.
We found that gut microbiota eradication or GF status prevents the development of mechanical hyperalgesia through its impact on DRG inflammatory responses to oxaliplatin. The exact mechanism underlying this role of gut microbiota remains to be elucidated. Recent studies show that gut microbiota determines the functional maturation of microglia in the central nervous system 15 , promotes neutrophils migration in inflammatory responses 16 and, notably, facilitates the migration of monocytes to kidneys following ischemic-reperfusion injury 17 . The present results demonstrate that gut microbiota is indispensable in oxaliplatin-induced mechanical hyperalgesia. LPS has been shown to be one of the key factors derived from gut microbiota that determine autoimmunity and inflammation 18 . Our data indicate that LPS enabled and augmented macrophages to secret inflammatory cytokines in response to oxaliplatin exposure, showing a synergy between signals derived from gut microbiota and the impact of oxaliplatin itself on immune cells. This synergy was further supported by the findings that LPS administration abrogated the protective effect offered by gut microbiota eradication ( Fig. 3a) .
Our findings further demonstrate that oxaliplatin is dependent on gut microbiota to exert not only its tumor-killing effect 3, 19 but also its crucial impact on the development of mechanical hyperalgesia, a major side effect associated with chemotherapy. These findings are not mutually exclusive to previous findings that oxaliplatin has neurotoxicity 7 . In addition, oxaliplatin may directly alter the gut microbiota that contributes to the development of chemotherapy-induced mechanical hyperalgesia. Previously, Amaral et al. found that carrageenan-induced inflammatory pain was attenuated in GF mice, suggesting a key role of gut microbiota in mediating inflammatory pain 20 . Our findings indicate that gut microbiota also plays a key role in mechanical hyperalgesia induced by oxaliplatin. Future studies are needed to examine whether gut microbiota is implicated in mechanical hyperalgesia induced by other chemotherapy agents.
MeThOds
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. (c) A permissive effect of LPS on production of IL-6 and TNF-α in macrophages. Macrophages were collected from peritoneal cavity for culture in the presence of LPS and oxaliplatin at indicated concentrations. IL-6 and TNF-α levels in culture supernatant were determined at 24 h after oxaliplatin and LPS stimulation with ELISA (enzyme-linked immunosorbent assay). One-way ANOVA followed by post hoc t test suggested that significant differences exist among three groups at given LPS concentration (*P < 0.05 vs. oxaliplatin 0 µM, **P < 0.05 vs. oxaliplatin 1 µM 
ONLINe MeThOds
Animals. All procedures and animal use were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee (IACUC) and were in accordance with the guidelines established by NIH and the International Association for the Study of Pain. Conventional SPF C56BL/7 mice and Sprague Dawley rats were purchased from the Jackson Laboratory and Charles Rivers Laboratory, respectively. All initial group assignments were randomized. Except for the indicated experiment using female mice, we used male mice (6-12 weeks of age) for the study. For gut microbiota eradication, SPF mice and rats were provided, ad libitum, with drinking water containing 0.5 g/L ampicillin, 0.5 g/L neomycin, 0.5 g/L metronidazole and 0.25 g/L vancomycin (all antibiotics from Sigma-Aldrich) with 3 g/L artificial sweetener Splenda, for 3 weeks. Antibiotics water was maintained during the entire experimental period for chemotherapyinduced pain. When necessary, gastric gavage of oral antibiotics was used. Antibiotics were renewed every other day. For the LPS administration experiment, LPS (Sigma L3012) was administered via gastric gavage at 3 mg/kg on days of oxaliplatin treatment and twice weekly afterwards. Germ-free (GF) mice were obtained from the COX-7 animal facility at the Massachusetts General Hospital. For the fecal transplantation experiment, freshly collected feces from SPF mice were diluted 1:10 with PBS, followed by gastric gavage of 0.3 mL per mouse, daily for two consecutive weeks. For intrathecal injection 21 , antibiotics were prepared in normal saline at the same concentration of oral feeding. Mice were anesthetized with isoflurane anesthesia and shaved around the lumbar spine. A 25-µL Hamilton syringe with a 30-gauge needle was inserted between the L5 and L6 vertebrae, and intrathecal access was identified by tail flick. We injected 5 µL of antibiotic solution or normal saline each time. Mice were injected intrathecally every other day starting from 3 weeks before oxaliplatin therapy and continuing through the entire experiment.
oxaliplatin therapy. To induce mechanical hyperalgesia, oxaliplatin (SAGENT Pharmaceuticals, IL) was administered intraperitoneally at 3 mg/kg for mice and 2 mg/kg for rats for five consecutive days at a total dose of 15 mg/kg and 10 mg/kg, respectively. For the in vitro culture experiment, oxaliplatin was diluted with DMEM culture medium (Gibco) at the indicated concentrations.
Behavioral tests. All behavioral experiments were carried out by investigators blind to treatment conditions. Animals were habituated to the test environment for two consecutive days (30 min per d) before baseline testing. Mechanical withdrawal threshold. A von Frey filament was perpendicularly applied to the plantar surface of each hind paw using an up-and-down approach 22,23 . A threshold force of response (in g) was defined as the first filament that evoked at least two withdrawals out of five applications. Seven or fewer filaments were applied to animals. Facial grooming was evaluated by counting the number of forepaw rubs and hindpaw scratches in a 10-min period 24 . GF animal testing was performed in a facility room with HEPA air filter and a testing hood with laminar flow. Test performers wore sterile gown and gloves. Testing enclosures were autoclaved before use. Of note, the GF behavioral testing period occurred over 3 weeks. We could not completely rule out potential contamination occurred during the testing period, despite surveillance Quantitative PCR was negative 25 for contamination.
Real-time PcR for cytokine genes. cDNA was prepared from 1,000 ng of total RNA, according to the protocol for SuperScript IV Reverse transcription (Invitrogen, Grand Island, NY). For each sample, real-time quantitative PCR was then performed using TaqMan (Thermo-Fisher) probes for Tnf, Il6 and Gapdh with Universal PCR Master Mix (Applied Biosystems) under the cycling conditions required in the Universal PCR Master Mix protocol. The expression of candidate genes in each group of samples was normalized to Gapdh to obtain a ∆Ct value and to calculate 2 −(mean ∆∆Ct) .
elISA. Levels of IL-6 and TNF-α were measured by ELISA (R& D Biosystems, Minneapolis, MN) according to the manufacturer's instructions. The lower detection limit was 1.8 pg/mL for Il-6 and 7.2 pg/mL for TNF-α. The assay plates were read at 450 nm and 540 nm. All samples were run in duplicate. lPS (endotoxin) assay. All materials used for both sample preparation and testing were pyrogen free. LPS concentrations in plasma and tissue homogenate were measured by an endotoxin assay based on a limulus amebocyte extract with a chromogenic limulus amebocyte lysate (LAL) assay (Pierce LAL Chromogenic Endotoxin Quantitation Kit). Samples were diluted in pyrogen-free water and heated to 70 °C for 10 min to inactivate inhibitor agents that could interfere with the assay. All samples were tested in triplicate, and results were accepted when the intra-assay coefficient of variation was 15%. The endotoxin content was expressed as endotoxin units per milliliter (EU/mL) or endotoxin units per 100 mg of tissue.
dnA extraction and quantification of fecal bacteria. Fecal DNA was extracted with DNA Stool Kit (MoBio) according to the manufacturer's instruction. The abundance of eubacteria in feces was measured by qPCR using a StepOnePlus instrument (Applied Biosystems) with the fecal DNA and 16S rRNA gene primers for eubacteria. The sequences of the primers are: ACT CCT ACG GGA GGC AGC AGT (UniF 340) and ATT ACC GCGGCT GGC (UniR 514). The realtime PCR program started with an initial step at 95 °C for 10 min, followed by 40 cycles of 95 °C 30 s and 60 °C 1 min. RT-PCR was done using SYBR Green Mastermix (Qiagen). Bacterial numbers was determined using standard curves constructed with DNA of Escherichia coli strain DH10α as reference bacteria. The 16S rRNA gene sequencing and data analysis were performed by BGI America (Cambridge, MA). Briefly, after amplicon based sequencing, OTUs were clustered using USEARCH (7.0.1090) with a 97% threshold. Greengene V201305 was used as reference database for taxonomic analysis. The MixOmics package for R was used for PLS-DA analysis. OTU rank curse was generated in R (V3.1.1).The tag number of each taxonomic rank (phylum, class, order, family, genus, species) or OTU in different samples were summarized in histograms generated in R (V3.1.1) [2] [3] [4] 18 . Sequencing data are available through NCBI BioProject PRJNA388399.
Bioluminescence assay. Mice were injected with 100mg/kg luminescent probe L-012 (Wako, Richmond, VA) 3 d after oxaliplatin injection. Within 3-5 min after injection, mice were killed for analysis and (lumbar) L3-L5 DRGs were obtained for an IVIS Spectrum (Xenogen, Alameda, CA) study. L-012 shows luminescence after chemical reaction with ROS. To calculate bioluminescence, radiance (photons/s/cm 2 /sr) was obtained within 15 min after L-012 injection.
Platinum concentration by IcP-mS analysis.
Each tissue sample was transferred to a glass sample vial and the sample weight was recorded. The sample was then digested with 1.5:4% HNO 3 :HCl to 20 mL volume at 37 °C overnight. Elemental analysis was completed using ICP-MS (Agilent Technologies, 8800 ICP-MS-QQQ). Calibration samples were prepared from serial dilutions of 1-µg/g and 10-ng/g Pt (NIST SRM 3140) solutions. Briefly, 10-, 25-, 50-, 75-, 100-, 150-and 200-pg/g standards were prepared by diluting 0.10, 0.25, 0.50, 0.75, 1.0, 1.5 and 2.0 mL of a 1-ng/g Pt solution. Each prepared standard was transferred to an 18-mL LDPE sample vial. The standards were diluted to a total of 10 mL using 1.5:4% HNO 3 :HCl solution. The weights of the empty vial, the vial containing the sample and the vial containing the final dilution were recorded. The exact concentration in each standard was determined by difference. The three analyzed elements were platinum (Analyte), lutetium (internal standard) and dysprosium (internal standard). Samples were run in triplicate, with each one or the triplicate consisting of 10 measurement repetitions. A calibration curve was constructed from the external calibration samples. The limit of detection (LOD) for the sample run was 0.48 pg/g. The limit of quantitation (LOQ) was also determined using the formula above, with k = 10. The LOQ for the ICP-MS run was 1.6 pg/g.
Flow cytometry.
For DRG staining, mice were anesthetized by isoflurane anesthesia followed by perfusion through left ventricle cannulation with a 20gauge needle. For each mouse, 20 mL of ice-cold normal saline were perfused to minimize blood contamination in the sample. Six DRG samples were obtained from each mouse. DRG samples were minced and digested with Liberase TL (Roche) at 37 °C for 60 min in RPMI-1640 medium with intermittent vortex. The samples were then filtered through a nylon membrane with 60-µm pores, followed by centrifugation. A Percoll (Sigma) gradient (70-40%) was used for cell isolation. For peripheral blood staining, we used 20 µL of peripheral blood obtained from retro-orbital veins. For cultured macrophage staining, macrophages cultured in RPMI-1640 were washed in PBS three times, followed by a brief trypsin treatment to detach cells from culture plate. Flow cytometry staining was performed at room temperature (22-24 °C) for 10 min, except for annexin V and 7-AAD staining. Antibodies (anti-CD3, catalog #100235; anti-CD4, catalog #100413; anti-CD11b, catalog #101222; anti-CD335, catalog #137617; anti-CD11c, catalog #117309; anti-Ly-6G, catalog #127623; antiannexin V, catalog #640905; and anti-7-AAD, catalog #420403) were obtained from BioLegend. For annexin V and 7-AAD staining, binding buffers containing 140 mM NaCl, 4 mM KCl, 0.75 mM MgCl 2, 2.5mM CaCl 2 and 10 mM HEPES in DDW were used at 0.2 mL per sample. Annexin V and 7-AAD were added to the sample 10 min before acquisition by flow cytometer. All samples were acquired by LSR II (BD) flow cytometer. Data were analyzed with Flowjo (FlowJo) software. macrophage isolation and culture 26 . Mice were killed for analysis and soaked in 70% ethanol. We injected 10 mL of cold PBS to the peritoneal cavity, followed by needle aspiration. Aspirated fluid was centrifuged and cells (including neutrophils and macrophages) were resuspended in DMEM medium. A total of 4 × 10 5 cells/well was added to a 24-well plate. The cells were allowed to adhere to the culture plate for 2 h at 37 °C. Nonadherent cells were removed by gently washing three times with warm PBS. Adherent cells were macrophages and were used for subsequent culture in the presence of LPS and oxaliplatin at desired concentrations.
Statistical analysis and sample size. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications 27 . Data distribution was assumed to be normal, but this was not formally tested. Behavioral data were analyzed using two-way ANOVA, repeated across timepoints and groups. One-way ANOVA was used to analyze the data from various assays (qPCR, ELISA). Post hoc Waller-Duncan k-ratio t-tests (two-tailed) were performed to determine the source(s) of differences. SPSS 12.0 software was used for the statistical analyses. All data were expressed as mean ± s.e.m. and the statistically significant level was set at P < 0.05. A Supplementary methods checklist is available.
data availability. The data that support the findings of this study are available from the corresponding author upon reasonable request. For experiments reported in the text but not in the figures, please use the paragraph number instead of the figure number.
Note: Mean and standard deviation are not appropriate on small samples, and plotting independent data points is usually more informative. When technical replicates are reported, error and significance measures reflect the experimental variability and not the variability of the biological process; it is misleading not to state this clearly. If so, where is this reported (section, paragraph #)?
We stated in the figure legends that shown staining represent six individual animals in each group. Summary of Fig2a staining were plotted in Fig 2b. a. How were the criteria for exclusion defined?
Where is this described (section, paragraph #)?
b. Specify reasons for any discrepancy between the number of animals at the beginning and end of the study.
 Reagents 1. Have antibodies been validated for use in the system under study (assay and species)?
Yes a. Is antibody catalog number given?
Where does this appear (section, paragraph #)?
Online methods, paragraph #10. (cat# CD3-100235;CD4 100413; CD11b 101222; CD335 137617; CD11c 117309; Ly-6G 127623, AnnexinV 640905; 7-AAD 420403).
b. Where were the validation data reported (citation, supplementary information, Antibodypedia)?
All these antibodies have references in their company data sheet. 
